enGene appoints Theresa Podrebarac as CMO
Dr. Podrebarac is a 15-year industry veteran with extensive pharmaceutical drug development expertise from large pharma and biotech companies.
Dr. Podrebarac joins enGene from AbbVie where she served as Vice President, Immunology Clinical Development.
At AbbVie, she led the Immunology Therapeutic Council to develop the future vision for the company's portfolio and introduced integrated biomarker techniques and quantitative decision tools to early clinical development.
Previously, Dr. Podrebarac was Vice President of Early Clinical Development and Immunology at Biogen.
Prior to Biogen, she served as Vice President and Head of Rheumatology Global Clincal Development at EMD Serono and provided strategic leadership to the Autoimmunity, Inflammation and Emerging Therapies Unit.
Dr. Podrebarac is a board certified rheumatologist who earned her medical degree from the University of Western Ontario and completed post-doctoral training in T cell immunology at Harvard University and Brigham and Women's Hospital in Boston. ■